102 results
Page 4 of 6
8-K
EX-99.1
n0kjb1smhsvv775swdm
21 Dec 20
First gene therapy to receive full EU marketing authorization for eligible MLD patients
7:03am
8-K
EX-99.1
k8nxuxhbcsyir2
8 Dec 20
Other Events
7:03am
8-K
EX-99.1
httm2k2jcyw6z1
19 Nov 20
Other Events
7:03am
8-K
EX-99.1
r2bb913b
12 Nov 20
NOD2 mutation revealed as Crohn’s disease (CD) genetic target, associated with 7-10% of all CD cases in the U.S. and Europe
4:18pm
8-K
EX-99.1
mta4f5hubht5v
3 Nov 20
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
x2ap1ar6huyzr 72f2
16 Oct 20
Other Events
6:03am
8-K
EX-99.1
avth leo7n5e5
28 Sep 20
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
7:03am
8-K
EX-99.1
5ouyyohk547k2p
1 Sep 20
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
7:03am
S-8
EX-99.2
midj czryu
6 Aug 20
Registration of securities for employees
4:07pm
8-K
EX-99.1
j8hgksgq
6 Aug 20
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
5hwil20m5tpj
20 Jul 20
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
7:03am
8-K
EX-99.1
0p4l0u
15 Jul 20
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
7:03am
8-K
EX-99.1
ego64ol
9 Jul 20
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
7:03am
8-K
EX-99.1
feecgln8 swwyfuqadcv
15 May 20
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
6:03am
10-Q
nx8ps7tv2appe5o
7 May 20
Quarterly report
4:03pm
8-K
EX-99.1
8np 7r0y1t
7 May 20
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
7:03am
DEF 14A
7ey8 wff8
29 Apr 20
Definitive proxy
4:02pm
8-K
EX-99.1
dfmpkql178 imqh
27 Apr 20
Other Events
7:05am